The Filing Desk

Grail

GRAL · Nasdaq · Health Care · Financials, fiscal 2022 to 2025

GRAL · Last close · November 13, 2026
$115.89
Value Grail yourself

Grail's revenue rose 17.2% to $147 million in fiscal 2025. Its operating margin was −382.0%, up from −1,743.0% a year earlier. Free cash flow was −$300 million. The diluted share count rose 15.2%.

GRAIL, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 12, 2026 · 0001628280-26-017319 Updated
Revenue
$147M
17.2%
Operating margin
−382.0%
1361.0 pts
Net income
−$408M
 
Free cash flow
−$300M
 
Return on equity
−16.1%
 
Market cap
$5.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Grail does

GRAIL sells Galleri, a blood test that screens for many types of cancer at once and points to where in the body a cancer signal may have come from. The company describes itself as commercial-stage, meaning the test is already on sale. Galleri is currently offered through partnerships with healthcare systems, employers, digital health platforms, payors and life insurance providers.

Almost all of its revenue comes from Galleri. GRAIL says it has run what it believes is the largest clinical program in genomic medicine, and it has submitted a pre-market approval application to the U.S. Food and Drug Administration, with the last part sent in January 2026. It reported results from two large studies, PATHFINDER 2 and the NHS-Galleri trial, and included some of them in that application.

The NHS-Galleri trial did not meet its main goal, which the company lists as a risk. GRAIL has a limited operating history and has lost money in every period since it began.

Its biggest risks, as it describes them

  • A substantial majority of its revenue comes from Galleri, so it depends heavily on one test.
  • The NHS-Galleri trial did not meet its main goal, which may hurt its business and its approval efforts.
  • Insurers and other payors may not cover Galleri or may pay too little for it.
  • The test may not perform in real-world use as it did in clinical studies.
  • It has lost money in every period since it began and expects more net losses.
From Grail's annual report on Form 10-K, filed March 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Grail lost money in fiscal 2025: a net loss of $408 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25
Cash and short-term investments24297761902
Debt incl. finance leases————
Net debt (negative means net cash)————
Net debt to EBITDA————
Debt to equity————
Interest coverage————
Current ratio—0.9x10.7x12.0x
Quick ratio—0.9x10.7x12.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Grail's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Grail shares on the open market, and 5 insiders sold $110.6 million, $7.5 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 21, 2026Joshua J. OfmanChief Executive Officer, DirectorSold plan61,452$97.74$6.0 millionForm 4
Sep 21, 2026Aaron FreidinChief Financial OfficerSold plan4,100$93.34$382,682Form 4
Aug 27, 2026Aaron FreidinChief Financial OfficerSold plan7,900$85.01$671,579Form 4
Aug 27, 2026Joshua J. OfmanChief Executive Officer, DirectorSold plan5,000$85.02$425,100Form 4
Jun 4, 2026Andrew John PartridgeChief Growth OfficerSold1,491$61.08$91,070Form 4
Apr 8, 2026Robert P RagusaChief Executive Officer, DirectorSold123,502$49.92$6.2 millionForm 4
Apr 8, 2026Joshua J. OfmanPresident, DirectorSold61,665$49.92$3.1 millionForm 4
Apr 8, 2026Aaron FreidinChief Financial OfficerSold45,806$49.92$2.3 millionForm 4
Mar 9, 2026Robert P RagusaChief Executive Officer, DirectorSold7,461$47.89$357,296Form 4
Mar 9, 2026Joshua J. OfmanPresidentSold2,937$47.89$140,650Form 4
Mar 9, 2026Aaron FreidinChief Financial OfficerSold2,492$47.89$119,340Form 4
Mar 5, 2026Robert P RagusaChief Executive Officer, DirectorSold980$53.01$51,950Form 4
The latest 12 of 22 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−586.2%−428.8%−186.6%
Altman Z''—−8.53−2.86
Accruals ratio—−42.0%−3.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positive—FailFail
Cash from operations is positiveFailFailFail
Return on assets rose——Pass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rose—PassPass
Share count didn't risePassFailFail
Gross margin rose———
Revenue rose relative to assets——Pass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Grail side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
GrailFY2517.2%−382.0%−203.8%———
SchrödingerFY2523.3%−65.2%4.9%———Compare
Castle BiosciencesFY253.7%−12.4%8.2%−19.1%—4Compare
CareDxFY2513.8%−8.1%—−20.0%—4Compare
GeneDxFY2540.0%−3.1%3.3%−5.3%—6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

4 years of figures

Fiscal yearFY22FY23FY24FY25
Income statement
Revenue5693126147
Revenue growth—67.6%34.9%17.2%
Gross profit————
Research and development330339322196
Operating income−5,443−1,515−2,189−562
Net income−5,399−1,466−2,027−408
Diluted EPS (US$)−173.89−47.21−63.54−11.11
Diluted shares (millions)31313237
Cash flow
Cash from operations−561−596−577−299
Capital expenditure231351
Free cash flow−584−609−582−300
Dividends paid0000
Share buybacks0000
Acquisitions0000
Stock-based compensation76978658
Balance sheet at fiscal year end
Cash and short-term investments24297761902
Debt incl. finance leases————
Total assets—3,9142,9832,922
Total liabilities—268480344
Shareholders' equity——2,5032,578
Margins and ratios
Gross margin————
Operating margin−9,798.2%−1,627.6%−1,743.0%−382.0%
Net margin−9,719.4%−1,574.2%−1,613.9%−277.5%
Free cash flow margin−1,051.6%−653.8%−463.7%−203.8%
Rule of 40 (growth + FCF margin)—−586.2%−428.8%−186.6%
Return on capital————
Return on equity———−16.1%
Return on assets——−58.8%−13.8%
Net debt to EBITDA————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Grail's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Grail.